PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
GERM vs. IHE
Performance
Return for Risk
Drawdowns
Volatility
Dividends

GERM vs. IHE

Last updated Jun 23, 2026

GERM (Amplify Treatments, Testing and Advancements ETF) and IHE (iShares U.S. Pharmaceuticals ETF) are both Health & Biotech Equities funds - GERM tracks the Prime Treatments, Testing and Advancements Index while IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index. Both are passively managed. Over the past year, GERM returned 0.00% vs 45.56% for IHE. GERM charges 0.68%/yr vs 0.42%/yr for IHE.

Performance

GERM vs. IHE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Treatments, Testing and Advancements ETF (GERM) and iShares U.S. Pharmaceuticals ETF (IHE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
—
5Y*
—
10Y*
—

IHE

1D
0.83%
1M
1.54%
YTD
9.89%
6M
8.65%
1Y
45.56%
3Y*
17.81%
5Y*
10.40%
10Y*
8.82%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GERM vs. IHE - Yearly Performance Comparison

2026 (YTD)20252024
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%
IHE
iShares U.S. Pharmaceuticals ETF		9.89%31.69%-7.21%

GERM vs. IHE - Sectors Allocation Comparison

Sectors
GERM
IHE

Healthcare

99.3%
100.0%

Financial Services

0.4%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

GERM
99.3%
IHE
100.0%

Financial Services

GERM
0.4%
IHE

-

Basic Materials

GERM

-

IHE

-

Communication Services

GERM

-

IHE

-

Consumer Cyclical

GERM

-

IHE

-

Consumer Defensive

GERM

-

IHE

-

Energy

GERM

-

IHE

-

Industrials

GERM

-

IHE

-

Real Estate

GERM

-

IHE

-

Technology

GERM

-

IHE

-

Utilities

GERM

-

IHE

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Amplify Treatments, Testing and Advancements ETF

iShares U.S. Pharmaceuticals ETF

Often compared with GERM:
GERM vs. SBIOGERM vs. EQRRGERM vs. XBIGERM vs. GDOCGERM vs. ARKGGERM vs. XLVGERM vs. MDEV
Often compared with IHE:
IHE vs. PPHIHE vs. XPHIHE vs. XLVIHE vs. VYMIHE vs. PJPIHE vs. IAKIHE vs. BBP

Return for Risk

GERM vs. IHE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
GERM

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

IHE
IHE Risk / Return Rank: 8686
Overall Rank
IHE Sharpe Ratio Rank: 8686
Sharpe Ratio Rank
IHE Sortino Ratio Rank: 8989
Sortino Ratio Rank
IHE Omega Ratio Rank: 8080
Omega Ratio Rank
IHE Calmar Ratio Rank: 9090
Calmar Ratio Rank
IHE Martin Ratio Rank: 8484
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERM vs. IHE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and iShares U.S. Pharmaceuticals ETF (IHE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

GERMIHEDifference
Sharpe ratioReturn per unit of total volatility

—

2.67

—

Sortino ratioReturn per unit of downside risk

—

3.86

—

Omega ratioGain probability vs. loss probability

—

1.45

—

Calmar ratioReturn relative to maximum drawdown

—

5.40

—

Martin ratioReturn relative to average drawdown

—

16.62

—

GERM vs. IHE - Sharpe Ratio Comparison

Loading charts...

Drawdowns

GERM vs. IHE - Drawdown Comparison

The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum IHE drawdown of -38.20%. Use the drawdown chart below to compare losses from any high point for GERM and IHE.

Loading charts...

Drawdown Indicators

GERMIHEDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-38.20%

+38.20%

Max Drawdown (1Y)

Largest decline over 1 year

0.00%

-8.47%

+8.47%

Max Drawdown (3Y)

Largest decline over 3 years

—

-15.92%

—

Max Drawdown (5Y)

Largest decline over 5 years

—

-16.03%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-29.59%

—

Current Drawdown

Current decline from peak

0.00%

-2.26%

+2.26%

Average Drawdown

Average peak-to-trough decline

0.00%

-7.90%

+7.90%

Ulcer Index

Depth and duration of drawdowns from previous peaks

0.00%

2.75%

-2.75%

Volatility

GERM vs. IHE - Volatility Comparison

The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while iShares U.S. Pharmaceuticals ETF (IHE) has a volatility of 5.20%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than IHE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading charts...

Volatility by Period

GERMIHEDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.00%

5.20%

-5.20%

Volatility (6M)

Calculated over the trailing 6-month period

0.00%

12.59%

-12.59%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

17.20%

-17.20%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

16.27%

-16.27%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

18.07%

-18.07%

GERM vs. IHE - Expense Ratio Comparison

GERM has a 0.68% expense ratio, which is higher than IHE's 0.42% expense ratio.

Dividends

GERM vs. IHE - Dividend Comparison

GERM has not paid dividends to shareholders, while IHE's dividend yield for the trailing twelve months is around 1.58%.

PositionTTM20252024202320222021202020192018201720162015
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
IHE
iShares U.S. Pharmaceuticals ETF		1.58%1.76%1.73%1.39%2.01%1.49%1.19%1.40%1.25%1.36%0.92%1.93%

Frequently Asked Questions

IHE has higher volatility (5.20%) compared to GERM (0.00%). In terms of maximum drawdown, GERM dropped 0.00% vs IHE's -38.20%.

On 1-year performance, IHE leads with 45.56% vs 0.00% for GERM. On fees, IHE is cheaper at 0.42% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 1-year period, IHE has performed better with a 45.56% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IHE is cheaper with a 0.42% expense ratio, compared with 0.68% for GERM.

IHE has the higher dividend yield at 1.58%, compared with 0.00% for GERM.

GERM tracks Prime Treatments, Testing and Advancements Index, while IHE tracks Dow Jones U.S. Select Pharmaceuticals Index. They also come from different issuers: Amplify and iShares. Their fees differ too: 0.68% for GERM and 0.42% for IHE.

Portfolio Optimizer

Find the right allocation for GERM and IHE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer